Holcomb Meredith A, Burton Jane A, Dornhoffer James R, Camposeo Elizabeth L, Meyer Ted A, McRackan Theodore R
Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, U.S.A.
Laryngoscope. 2019 Mar;129(3):748-753. doi: 10.1002/lary.27528. Epub 2018 Nov 28.
To determine indications, surgical efficacy, and audiologic outcomes of replacing Advanced Bionics Clarion C1.2 internal devices (Advanced Bionics, LLC, Valencia, CA) as a means of technology upgrade.
Retrospective review, case series.
Ten patients were initially implanted as a child (mean age = 3.87 years) and underwent cochlear implant reimplantation (CIR) with current Advanced Bionics internal device as a young adult (mean duration of implant use = 15.66 years). Demographic data and pre- and post-CIR speech perception scores were collected.
Technology upgrade was the primary (9) or secondary (1) motivation for CIR. No surgical complications were noted, and full insertion was obtained in nine cases. Intraoperative impedance levels and neural response imaging measures were within normal limits for eight patients. At most recent post-CIR follow-up evaluation, all patients (100%) performed within or better than the 95% confidence interval of their pre-CIR word and sentence recognition scores; and 55.6%, 50.0%, and 50.0% of patients performed above the 95% confidence interval of their pre-CIR scores for the CNC words, sentences in quiet, and sentences in noise, respectively.
Post-CIR audiological benefit was stable or improved compared to pre-CIR results in all categories by 3 months after reactivation. Given these results, patients who are unable to use the most current external processors due to incompatibility with a legacy internal device could consider reimplanation to optimize their overall performance with a cochlear implant.
4 Laryngoscope, 129:748-753, 2019.
确定更换先进生物电子公司(Advanced Bionics)的Clarion C1.2植入式装置(先进生物电子公司,加利福尼亚州瓦伦西亚)作为技术升级手段的适应症、手术疗效及听力学结果。
回顾性病例系列研究。
10例患者儿童期首次植入(平均年龄3.87岁),成年后(植入使用平均时长15.66年)使用先进生物电子公司当前的植入式装置进行了人工耳蜗再植入(CIR)。收集了人口统计学数据以及CIR前后的言语感知评分。
技术升级是CIR的主要(9例)或次要(1例)动机。未观察到手术并发症,9例实现了完全植入。8例患者的术中阻抗水平和神经反应成像测量值在正常范围内。在CIR后的最近一次随访评估中,所有患者(100%)的表现处于或优于其CIR前单词和句子识别分数的95%置信区间;分别有55.6%、50.0%和